Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.61 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23453856 | 1.00 | GLA (0.61) | GLAPAOXCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL954925 | 0.98 | GLA (0.57) | GLAPAOXCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL8194848 | 0.95 | GLA (0.55) | GLAPAOXCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL21122189 | 0.90 | GLA (0.50) | GLAPAOXCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL24732015 | 0.90 | CYP1A2 (0.52) | GLAPAOXCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL6536452 | 0.88 | GLA (0.67) | GLAPAOXCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL3973280 | 0.88 | GLA (0.67) | GLAPAOXCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL7027263 | 0.88 | GLA (0.67) | GLAPAOXCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL1069692 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL1128155 | 0.87 | SMN1; SMN2 (0.64) | GLAPAOXCYP1A2MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3415151-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | The University of British Columbia (CA) | 2018-12-19 | — | — | EP | disclosed |
| EP-2282724-B1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-09-05 | — | — | EP | disclosed |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-08-09 | — | — | US | disclosed |
| US-9968554-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-05-15 | — | — | US | disclosed |
| US-20140356417-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-12-04 | — | — | US | disclosed |
| US-8790691-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-07-29 | — | — | US | disclosed |
| US-8568772-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-29 | — | — | US | disclosed |
| US-8545877-B2 | Modified drugs for use in liposomal nanoparticles | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-01 | — | — | US | disclosed |
| US-8545876-B1 | Modified drugs for use in liposomal nanoparticles | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-01 | — | — | US | disclosed |
| US-20130236534-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2013-09-12 | — | — | US | disclosed |
| US-20130230582-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2013-09-05 | — | — | US | disclosed |
| US-20130230583-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2013-09-05 | — | — | US | disclosed |
| US-8324410-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-12-04 | — | — | US | disclosed |
| US-20120237591-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-09-20 | — | — | US | disclosed |
| US-20110165225-A1 | Modified Drugs for Use in Liposomal Nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-07-07 | — | — | US | disclosed |
| EP-2282724-A2 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | The University Of British Columbia (CA) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009141738-A2 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-11-26 | — | — | WO | disclosed |
| EP-1644338-A1 | 2, 4, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | Aponetics AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004087679-A1 | 2, 4, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | APONETICS AG (CH) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230582-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | GLA 2373/4885CA2 2568/4885PAOX 2515/4885 |
| US-20110165225-A1 | Modified Drugs for Use in Liposomal Nanoparticles | ABCB11, SLC47A1, ABCB1 | GLA 1510/4885CA2 3355/4885PAOX 2984/4885 |
| US-20120237591-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | GLA 2373/4885CA2 2568/4885PAOX 2515/4885 |
| US-20130236534-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | GLA 2373/4885CA2 2568/4885PAOX 2515/4885 |
| US-20130230583-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | GLA 2373/4885CA2 2568/4885PAOX 2515/4885 |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | GLA 1510/4885CA2 3355/4885PAOX 2984/4885 |
| US-20140356417-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | GLA 1510/4885CA2 3355/4885PAOX 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.